

Nemaura Medical Inc

10:20 07 Aug 2019

Nemaura launches shipments of its SugarBEAT glucose monitor to the UK

Nemaura Medical Inc (NASDAQ:NMRD) has launched shipments of its SugarBEAT continuous glucose monitors to patients in the United Kingdom, the company announced Wednesday.

The wave of shipments is the company's first foray into the European market after receiving its CE mark, an EU seal of approval, in May.

The SugarBEAT monitor works for patients with diabetes or prediabetes by testing their blood glucose levels using a sensor on the skin, rather than using a needle to puncture the skin and draw a blood sample.

READ: Nemaura receives \$8 million credit facility from major shareholders "We are very pleased to have commenced the first phase of our commercial launch," CEO Faz Chowdhury said in a statement. "This represents a major achievement for the company as we transition from product development to a full-fledged commercial organization."

The company already has an eager British clientele. Nemaura reported that its UK licensee has registered more than 17,000 expressions of interest from potential users on its website.

The Loughborough, England-based company plans to present data from its first European users at the European Association for the Study of Diabetes conference in Barcelona on September 19.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Price: 4.6

Market Cap: \$95.72 m

1 Year Share Price Graph



December 2018 June 2019 December 20

Share Information

Code: NMRD

Listing: NASDAQ

52 week High Low
19.3 4.206

Sector: Medical technology & services

Website: www.nemauramedical.com

Company Synopsis:

Nemaura Medical Inc. is a medical technology company which has developed sugarBEAT® as a non-invasive, affordable and flexible continuous glucose monitor (CGM) designed to improve glucose management for all people with diabetes and pre-diabetics.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability,

value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Nemauro Medical Inc named herein, including the promotion by the Company of Nemauro Medical Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).